Key Insights

Highlights

Success Rate

86% trial completion

Published Results

61 trials with published results (12%)

Research Maturity

211 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

6.6%

33 terminated out of 499 trials

Success Rate

86.5%

-0.1% vs benchmark

Late-Stage Pipeline

31%

156 trials in Phase 3/4

Results Transparency

29%

61 of 211 completed with results

Key Signals

61 with results86% success33 terminated

Data Visualizations

Phase Distribution

393Total
Not Applicable (54)
Early P 1 (4)
P 1 (91)
P 2 (88)
P 3 (46)
P 4 (110)

Trial Status

Completed211
Unknown141
Recruiting48
Terminated33
Active Not Recruiting30
Not Yet Recruiting22

Trial Success Rate

86.5%

Benchmark: 86.5%

Based on 211 completed trials

Clinical Trials (499)

Showing 20 of 20 trials
NCT07595159Phase 1CompletedPrimary

A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B

NCT07600788Phase 1RecruitingPrimary

A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

NCT07635186Phase 2RecruitingPrimary

A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B

NCT07146100RecruitingPrimary

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

NCT06829329Phase 2Active Not RecruitingPrimary

Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

NCT07069569Phase 2RecruitingPrimary

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

NCT02863757RecruitingPrimary

Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

NCT07730736CompletedPrimary

Analysis of Clinical Characteristics of Chronic Hepatitis B Combined With MAFLD in Different TCM Syndrome Types

NCT06092333Phase 2RecruitingPrimary

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT07709520Phase 2RecruitingPrimary

Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B

NCT05630820Phase 3CompletedPrimary

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

NCT05630807Phase 3CompletedPrimary

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

NCT07573943Phase 4RecruitingPrimary

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

NCT07684209Not Yet RecruitingPrimary

A Study on the Consistency Evaluation of Digital PCR Technology for Quantitative Detection of HBV Nucleic Acid

NCT06638320Recruiting

Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection

NCT02932150Phase 2Active Not RecruitingPrimary

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

NCT05841095Phase 1Active Not RecruitingPrimary

Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

NCT06513286Phase 1RecruitingPrimary

TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

NCT05727267Phase 1CompletedPrimary

A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

NCT07589400Phase 1Not Yet Recruiting

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B

Scroll to load more

Research Network

Activity Timeline